A global phase 2 clinical trial for people with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease
To assess the safety of an investigational drug, aducanumab in people with mild cognitive impairment due to Alzheimer’s disease, or mild Alzheimer’s disease.
The investigational drug
Aducanumab (BIIB037) is a human recombinant monoclonal antibody (mAb). It is thought that aducanumab may have the potential to reduce harmful amyloid plaques (abnormal deposits) that form in the brains of people with Alzheimer’s disease, possibly slowing the progress of the disease.
Key eligibility criteria
- Men and women
- 50-85 years old
- Have a diagnosis of mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease
- Do not have other significant/uncontrolled medical issues
- Are able to undergo multiple Magnetic Resonance Imaging (MRI) tests of the brain
- Have a study partner or caregiver who can attend at least one screening appointment and provide information about their health
- Approximately 1 year 6 months
- Optional potential long-term extension study